http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11344121-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1dd98ad4ee076841fec541542f952f58 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A47B2097-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2440-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2440-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-368 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A47B97-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/F16M13-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A44B11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6875 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-689 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A47B97-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A44B11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/F16M13-02 |
| filingDate | 2017-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b94bac6a954d00ed85f47f1bb6bbe730 |
| publicationDate | 2022-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-11344121-B2 |
| titleOfInvention | Methods of predicting preeclampsia using biomarkers |
| abstract | The subject invention pertains to biomarkers for identifying a subject as having high risk of the development PE. The biomarkers presented herein include miRNAs, post-translational modification of histone proteins, amount, expression and/or activity of histone or DNA modifying enzymes and methylation of sites in the genomic DNA. In certain embodiments, increased miR-17, increased acetylation of H4 histone protein, decreased amount, expression and/or activity of HDACS mRNA or protein or increased methylation of DNA at the genomic site CYP19A1 in the blood, serum or plasma of a subject compared to that of a control subject is used to predict the development of PE in the subject. The invention also provides kits and reagents to conduct assays to quantify biomarkers described herein. The invention further provides the methods of treating and/or managing PE in a subject identified as having a high risk of the development of PE. |
| priorityDate | 2016-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 897.